Pages that link to "Q34184162"

The following pages link to The cost-effectiveness of acetaminophen, NSAIDs, and selective COX-2 inhibitors in the treatment of symptomatic knee osteoarthritis. (Q34184162):

Displaying 22 items.

• Clinical efficacy and safety of glucosamine, chondroitin sulphate, their combination, celecoxib or placebo taken to treat osteoarthritis of the knee: 2-year results from GAIT (Q24602794) (← links)
• A comparison of cost effectiveness using data from randomized trials or actual clinical practice: selective cox-2 inhibitors as an example (Q28472098) (← links)
• EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). (Q31119321) (← links)
• Nonsteroidal anti-inflammatory drugs and hepatic toxicity: a systematic review of randomized controlled trials in arthritis patients (Q33214797) (← links)
• Cost-effectiveness analyses of osteoarthritis oral therapies: a systematic review (Q34384075) (← links)
• Comparison of gastrointestinal adverse effects between cyclooxygenase-2 inhibitors and non-selective, non-steroidal anti-inflammatory drugs plus proton pump inhibitors: a systematic review and meta-analysis (Q34499039) (← links)
• Cost-effectiveness of pharmaceutical management for osteoarthritis pain: a systematic review of the literature and recommendations for future economic evaluation (Q34591000) (← links)
• Lifetime medical costs of knee osteoarthritis management in the United States: impact of extending indications for total knee arthroplasty (Q35576022) (← links)
• Allopurinol use and the risk of acute cardiovascular events in patients with gout and diabetes (Q36306524) (← links)
• Model-based evaluation of cost-effectiveness of nerve growth factor inhibitors in knee osteoarthritis: impact of drug cost, toxicity, and means of administration (Q36818355) (← links)
• Disease-modifying drugs for knee osteoarthritis: can they be cost-effective? (Q36894945) (← links)
• Cost-effectiveness analysis for joint pain treatment in patients with osteoarthritis treated at the Instituto Mexicano del Seguro Social (IMSS): Comparison of nonsteroidal anti-inflammatory drugs (NSAIDs) vs. cyclooxygenase-2 selective inhibitors. (Q37061561) (← links)
• Pharmacologic regimens for knee osteoarthritis prevention: can they be cost-effective? (Q37735333) (← links)
• Economic outcomes for celecoxib: a systematic review of pharmacoeconomic studies. (Q38042714) (← links)
• Impact of patient sample on costs of events in pharmacoeconomic models. (Q40041757) (← links)
• Bayesian cost-effectiveness analysis with two measures of effectiveness: the cost-effectiveness acceptability plane (Q44519601) (← links)
• Bayesian methods in cost-effectiveness studies: objectivity, computation and other relevant aspects (Q44698995) (← links)
• Cost-utility analysis of duloxetine in osteoarthritis: a US private payer perspective (Q45347178) (← links)
• Modelling the complete continuum of care using system dynamics: the case of osteoarthritis in Alberta (Q57759101) (← links)
• Use of gastroprotective agents in recommended doses in hospitalized patients receiving NSAIDs: a drug utilization study (Q79366464) (← links)
• Economic evaluation of tramadol/paracetamol combination tablets for osteoarthritis pain in the Netherlands (Q80391877) (← links)
• Cost-effectiveness and budget impact analysis of viscosupplementation with hylan G-F 20 for knee and hip osteoarthritis (Q92626575) (← links)